A biotech company focusing in fibrosis and autoimmunity was planning a reverse takeover transaction with a listed entity and required support in formulating its proxy statement (investor prospectus). Alacrita was commissioned to support the company by creating the business section of the prospectus.
Alacrita reviewed all relevant company information relating to its technology and product pipeline. It also worked with the company to define its overall strategy moving forward and to articulate company attributes and ethos. Together with extensive background research, the business section was structured to showcase all areas of the company and to highlight its approach in targeting fibrosis in autoimmune indications. The client was a company that we had worked for extensively in the past which meant we were already highly familiar with the company, its assets and technologies as well as its strategies. This in turn allowed us to complete the assignment within two weeks. The reverse merger was successfully completed and the company remains listed on NASDAQ.
We provide a range of pharma licensing services, taking a flexible approach that can include dovetailing with your existing internal capabilities and activities, or taking on full-responsibility for your out-licensing efforts.